AzTrials
AzTrials

Fracture of Medial MalleolusPhase 2/3NCT05245981

Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton

A Phase 2/3 study testing BRI.MAG 2 in people with Fracture of Medial Malleolus, run by Medical University of Graz at 1 site in Austria.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is a prospective, non-randomized trial for the treatment of fractures of the medial malleolus using lean, bioabsorbable, rare-earth element (REE) free, magnesium (Mg)-based biodegradable screws in the adult skeleton. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Fracture of Medial Malleolus
What is being tested?
BRI.MAG 2
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteAustria
Study dates
9 Jul 2018to 17 Jan 2023
Phase
Phase 2/3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with a dislocated fracture of the medial malleolus. Dislocation is defined as diastasis of the fracture in any direction of 2 mm or more.
  • Otherwise healthy patients (women and men) in the age-group 18 to 65 years
  • Subject has been informed of the nature of the study, agrees to participate and signs the approved consent forms. Included in this procedure is the standard information about the operation procedure.
  • Subject is able and willing to comply with all assessments in the study
  • Female subject with child-bearing potential perform a pregnancy test

Who cannot join

  • pathological fractures (f.e. bone cyst)
  • underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus)
  • poly-traumatized patient
  • multiple fractures at the same extremity
  • pregnant or breastfeeding women
  • inability or unwillingness to give informed consent

Trial locations and contacts

1 site in 1 country.

Austria1 site
  • Medical University of Graz

    Graz, Styria, 8036

Other trials in Austria

About this study

Official title: Pilot Study: Clinical Application of Mg Based Biodegradable Material for Fracture Fixation in the Adult Skeleton -First in Man Study

This study is a prospective, non-randomized trial for the treatment of fractures of the medial malleolus using lean, bioabsorbable, rare-earth element (REE) free, magnesium (Mg)-based biodegradable screws in the adult skeleton.

A total of 20 patients with isolated, bimalleolar, or trimalleolar ankle fractures were recruited between July 2018 and October 2019. Fracture reduction was achieved through bioabsorbable Mg-based screws composed of pure Mg alloyed with zinc (Zn) and calcium (Ca) (0.45 wt% Zn and 0.45 wt% Ca; ZX00). Visual analogue scale (VAS) and the presence of complications (adverse events) during follow-up (12 weeks) were used to evaluate the clinical outcomes. The functional outcomes were analyzed through the range of motion (ROM) of the ankle joint and the American Orthopaedic Foot and Ankle Society (AOFAS) score. Fracture reduction and gas formation were assessed using several plane radiographs.

Read the detailed description

The pilot study was designed as a prospective, nonrandomized trial for the treatment of displaced fractures of the medial malleolus with a lean, REE-free, Mg-based biodegradable implant in the adult skeleton. The trial was conducted according to the Good Clinical Practice (ISO 14155:2011) standard and the Declaration of Helsinki.The study was performed at the Department of Orthopaedics and Trauma at the Medical University of Graz and approved by the ethics committee (28 - 071 ex 15/16). A total of 20 subjects were recruited and operated on by three experienced surgeons in the centre between July 2018 and October 2019. Inclusion focused on adults aged between 18 and 65 years presenting with a displaced isolated medial malleolus fracture, a bimalleolar ankle fracture, or a trimalleolar ankle fracture. Fracture displacement was defined as diastasis of the fracture in any direction of 2 mm or more. Exclusion criteria were pathological fractures, underlying diseases (particularly bone diseases, kidney diseases, diabetes mellitus), polytraumatized patients, and pregnant or breastfeeding women.Written informed consent was obtained from each patient before the surgery. All radiological data were stored in a picture archiving and communication system (PACS). Fractures were classified according to the Herscovici system.25

Description of the bioresorbable device used: Ultra-high pure Mg (99.999%) was alloyed with Zn and Ca (0.45 wt% Zn and 0.45 wt% Ca) at 750°C under a protective gas atmosphere. Prepared screws had a length of 40 mm and a diameter of 3.5 mm. Implants were threaded at the distal part for use as traction screws.

Surgery: All patients were operated in a supine position. In case of a bimalleolar or trimalleolar fracture, the fibular and the dorsal tibial fragments were treated before the medial malleolus. Subsequently, two parallel Kirschner wires perpendicular to the medial malleolar fracture line were positioned with fluoroscopic control. A cannulated drill bit with 2.7 mm width was used for preparing the hole. Subsequently, one wire was removed and the ZX00 compression screw was inserted into the hole. Final fixation of the fracture was achieved with the second bioabsorbable Mg screw after removal of the second wire. The insertion torque of the screws was limited at a force of 1.5 newton metre with a torque handle. In all patients, no additional implants other than the Mg screws were used for the fixation of the medial malleolus. Patients with bimalleolar fractures and trimalleolar fractures were fixed with titanium plates and screws. Moreover, patients were immobilized with an under-knee plaster cast four to six weeks postoperatively and encouraged to attempt full weight-bearing as tolerated. Ankle movement exercises were started immediately after removal of the plaster.

Assessments and measurements: For each subject, the study consisted of assessments conducted preoperatively, immediately after operation and postoperative followup visits. During follow-up, complications including vital signs, erythema, swelling, pain, secretions, wound healing disorders, wound infections, or implant infections were recorded. Pain was assessed using visual analogue scale (VAS). Blood analysis and detection of Ca and Mg were recorded. Functional outcomes were evaluated through range of motion (ROM) in dorsal and plantar flexion. Additionally, the American Orthopaedic Foot and Ankle Society (AOFAS) score was performed after three months. Anteroposterior and lateral ankle radiographs (X-rays) were used to evaluate the fracture union and loss of reduction during follow-up. Postoperative radiograph evaluation was performed by two independent radiologists.

The study was registered retrospectively on Clinicaltrials.gov.

Being tested
BRI.MAG 2
Medical subject headings
Ankle Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BRI.MAG 2Device

    Patients presenting with dislocated isolated or combined fracture of the medialis malleolus, will be screened for eligibility. Every effort will be made to ensure eligibility of the patients prior to enrollment. 20 patients will be recruited for the study.

Study groups in NCT05245981
Study groupRoleWhat they receive
BRI.MAG 2ExperimentalPatients presenting with dislocated isolated or combined fracture of the medialis malleolus are eligible to receive the investigational device.
Receives: Device: BRI.MAG 2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Safety: Absence of (Serious) Adverse Events (SAE) throughout the study

    (Serious) Adverse Events defined as:

    • Secondary (post-op) diastasis of the distal tibiofibular joint assessed by two plane x-rays
    • Secondary diastasis of the malleolus medialis assessed by two plane x-rays.
    • Infection of the osteosynthesis assessed clinically and/or radiologically with the presence of at least three of the following signs: clinically: pain, swelling, warmth and redness in the infected area, chills and fever x-rays: regional osteopenia, periosteal reaction/thickening, Codman's triangle, focal bony lysis, loss of bony trabecular architecture, new bone apposition

    Measured: 3 years after surgery

  2. Primary Efficacy- Change of stability of the distal tibiofibular joint

    Stability of the distal tibiofibular joint reduced with two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks s and at 6 weeks

    Measured: after surgery, at 2 weeks and at 6 weeks

  3. Primary Efficacy- Change of stability of the fracture of the medial malleolus

    Stability of the fracture of the medial malleolus reduced by two BRI.MAG screws assessed by two plane x-rays after surgery, at 2 weeks and at 6 weeks

    Measured: after surgery, at 2 weeks and at 6 weeks

Secondary outcomes (2)
  1. Procedural success - operation procedure

    no change of the operation procedure from conventional to biodegradable

    Measured: 6 weeks

  2. Procedural success- complications

    Occurrence of interventional complications (break of material)

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Feb 2022
  2. Study start9 Jul 2018
  3. Primary completion17 Jan 2023
  4. Study completion17 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05245981
Sponsor's protocol ID
BRI.MAG 2
Status last verified
Jan 2023
First submitted
2 Feb 2022
Last updated
31 Jan 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing BRI.MAG 2 in people with Fracture of Medial Malleolus, run by Medical University of Graz at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Safety: Absence of (Serious) Adverse Events (SAE) throughout the study (time frame: 3 years after surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Jan 2023; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in